This article is more than 5 years old. Information may no longer be current.
Tetra submits orphan drug applications for cannabinoid-based treatments
Click Here to Manage Email Alerts
Tetra Bio-Pharma has submitted multiple orphan drug applications to the FDA for cannabinoid treatment of rare cancers and ocular diseases, the company announced in a release.
An orphan drug designation would allow for fast track approvals, tax credits on clinical research and reduced registration fees, the release said.
“Managing rare forms of cancer presents a huge challenge for physicians,” Tetra Bio-Pharma interim CEO and chief scientific officer Guy Chamberland, MSc, PhD, said. “Our R&D team has submitted numerous orphan drug designation applications to the FDA over the past 6 months, which not only holds promise to improve patient care but lines up with our corporate strategy to develop and commercialize cannabinoid prescription drug products for both rare cancers and ocular diseases in the United States.”
Previously the company entered into a partnership with Panag Pharma to develop cannabinoid-based prescription drugs for ocular inflammation and pain.